Review: Evolution of Cigarette Consumption Tax Policy in China (Pt.1)

Industry Insight by Huoxing Liaoran, translated by 2FIRSTS Reese & edited by Sophia
Aug.09.2024
Review: Evolution of Cigarette Consumption Tax Policy in China (Pt.1)
Since the "System of Tax Disbribution" reform in 1994, China's cigarette consumption tax policy has undergone several significant adjustments. These changes not only reflect the evolution of the economic situation but also reveal the profound impact of policy makers on the structure of the tobacco industry. Let's review how these policies, from the initial uniform tax rate to the complex graded tax system, have shaped today's cigarette market.

Special announcement:

2FIRSTS have been authorized by Source Media (WeChat Public Account "Huoxing Liaoran") to republish;

The entire text represents the views and stance of Huoxing Liaoran.


 

The third plenary session of the 20th Central Committee of the Communist Party of China was held in Beijing from July 15th to 18th, 2024. At the session, the Central Committee heard and discussed a report on the work of the Political Bureau, emphasized on further comprehensive and deepening reforms, advancing issues related to China's modernization, and considered and adopted the Resolution of the Central Committee of the Communist Party of China on Further Deepening Reform Comprehensively to Advance Chinese Modernization.

 

Review: Evolution of Cigarette Consumption Tax Policy in China (Pt.1)

 

Speculation in the public suggests that the country is soon to introduce a trillion-level consumption tax reform. China's consumption tax is a central tax, all of which is directly handed over to the state. According to data from the Ministry of Finance, in 2023, the national consumption tax revenue was 1.61 trillion yuan, accounting for 8.9% of the overall tax revenue. The consumption tax reform means that when local governments no longer have income from selling land, the nation will allocate some of the consumption tax revenue to them.

 

Cigarette consumption tax is the main part of the consumption tax. Now let's take a look at the changes in cigarette consumption tax policy together.

 

China's Adjustments to Cigarette Consumption Tax

 

The tobacco consumption tax in our country has been adjusted five times in 1994, 1998, 2001, 2009, and 2015.

 

1.Before 1994, tobacco was subject to the same 60% product tax as other industries.

 

After the implementation of the "System of Tax Disbribution" in 1994, the product tax was changed to Value Added Tax, and a new cigarette consumption tax was added. All types of cigarettes were taxed at a uniform rate of 40% based on the factory price. Through the implementation of this policy, tobacco production enterprises were encouraged to produce more high-end cigarettes with higher profits, shifting the product structure from low-end to high-end. Brands such as "Furong Wang" (1994), "Huanghelou" (1995), "Jiaozhi" (1995), and "Liqun" (1995) were born or revamped during this period.

 

Review: Evolution of Cigarette Consumption Tax Policy in China (Pt.1)
Image Source | Huoxing Liaoran

 

2. In 1998, the cigarette consumption tax system was reformed once again.

 

The tax system had changed from a single tax rate to a tiered tax rate, with three tiers: 50% for Category 1 tobacco, and 40% for Category 2 and 3, and 25% for Category 4 and 5. Following the implementation of this policy, sales of low-grade cigarettes had significantly increased, and some small and medium-sized tobacco factories had experienced a revival due to the tax reduction. During this period, tobacco consumption tax had been levied based on the ex-factory price, and was only collected at the production stage.

 

Review: Evolution of Cigarette Consumption Tax Policy in China (Pt.1)
Image Source | Huoxing Liaoran

 

3. In 2001, the adjustment of cigarette consumption tax was implemented using a composite taxation method that combined both volume-based and value-based taxes.

 

A fixed tax of 150 yuan was levied on every 50,000 cigarettes, while an ad-valorem tax was adjusted to two tiers: 45% for cigarettes with an allocation price of 50 yuan or more, and 30% for cigarettes with an allocation price below 50 yuan. Following the tax reform, the tax rate for low-end cigarettes had been increased from 25% to 30%, along with an additional fixed tax of 150 yuan per box, significantly increasing the tax burden on low-end cigarettes and reflecting a policy focused on supporting larger enterprises. Small and medium-sized enterprises producing less than 100,000 boxes of low-end cigarettes annually were experiencing severe losses, leading to closures and conversions, allowing for smoother restructuring of the cigarette industry.

 

Review: Evolution of Cigarette Consumption Tax Policy in China (Pt.1)
Image Source | Huoxing Liaoran

 

Conclusion

 

Looking back at the tax reforms from 1994 to 2001, we can see how policies have aimed to strike a balance between market demand and economic conditions. These adjustments not only altered the market landscape of the tobacco industry, but also laid the foundation for future policy making. In the next edition, I will delve into the adjustments made in 2009 and 2015 and their far-reaching impacts on the industry, so stay tuned.

 

 

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

New Zealand Associate Health Minister Casey Costello Warns on Illicit Cigarettes as Legal Tobacco Sales Halve Over Decade
New Zealand Associate Health Minister Casey Costello Warns on Illicit Cigarettes as Legal Tobacco Sales Halve Over Decade
New Zealand Associate Health Minister Casey Costello said legal tobacco sales in the country have fallen by more than half over the past decade, with sales declining more than 20% in 2025 compared with the previous year. She warned that the decline may not fully reflect lower smoking rates, as increased availability of illicit cigarettes could also be contributing. The government said it would continue strengthening tobacco and vape retail enforcement while monitoring the impact of illicit tobacco on public health and tax revenue.
Aug.26
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea's liquid-vape market is showing changes across raw-material imports, product types and sales channels after synthetic nicotine came under the Tobacco Business Act on April 24. Customs data show nicotine-analogue imports totaled 12,126 kilograms from April through August, while synthetic-nicotine imports over the same five months totaled 231,663 kilograms, just 39.3% of the amount imported in March alone. Physical liquid-vape stores tracked in Seoul and Gyeonggi Province fell 9.9%, unmanned outlets edged higher and online sales listings increased from 27,774 to 42,437. Government testing of 105 liquid inhalation products promoted as nicotine-free separately found nicotine in 13 and 6-methylnicotine in 12.
Sep.22
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan Industrial Co., Ltd. has filed a patent application for a cellulose-free scaffold material for nicotine pouches, proposing a combination of bioceramic material, polydextrose and sugar alcohols to replace conventional microcrystalline cellulose and cellulose derivatives. The filing aims to address issues including powdery mouthfeel, residue and limited release control, while also reducing reliance on existing cellulose-based patent portfolios. In patent examples, one fast-release formulation reached a nicotine release rate of 50% at 10 minutes and more than 90% at 20 minutes.
Sep.02
Exclusive Analysis | Smoore H1 Revenue Rises 19.9% Amid Growth Concentration, Profit Pressure and Slowing Momentum
Exclusive Analysis | Smoore H1 Revenue Rises 19.9% Amid Growth Concentration, Profit Pressure and Slowing Momentum
Smoore’s first-half 2026 revenue rose 19.9%, but the results revealed growing structural risks beneath the headline growth. Heat-not-burn contributed about 61% of incremental revenue and remains driven largely by one core customer, while traditional vaping markets diverged, own-brand growth slowed and China enterprise revenue declined further. Gross profit and adjusted profit lagged revenue growth, while second-quarter revenue growth slowed to about 1.9%, putting greater focus on the quality, concentration and sustainability of Smoore’s expansion.
Capital Markets
Aug.20
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore and four authorized U.S. CCELL distributors are asking a California federal court to permanently dismiss a core antitrust claim brought by direct purchasers. Plaintiffs allege that Smoore coordinated minimum wholesale prices, customer allocation and limits on price competition among distributors, amounting to a per se unlawful horizontal conspiracy. The defendants say the alleged conduct reflects ordinary vertical relationships between a manufacturer and its distributors. The court previously dismissed a similar claim, and the latest dispute centers on whether the second amended complaint adds sufficient facts to establish a horizontal agreement.
Sep.14
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22